Physician profile
Stacy Broussard
NPI 1932249356
$7,549.16
in general payments reported to CMS, 2019-2025
51 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $261 · 2021: $533 · 2022: $1,110 · 2023: $1,882 · 2024: $1,749 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.17 | 2019-2025 | |
| Lilly USA, LLC | $767.18 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $663.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $640.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $584.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $465.65 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $405.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.84 | 2019-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $361.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $211.40 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Kowa Pharmaceuticals America, INC. | $175.55 | 2019-2024 | Livalo, Zoryve |
| Exact Sciences Corporation | $164.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $156.23 | 2021-2025 | |
| Axsome Therapeutics, INC. | $142.55 | 2023-2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $137.27 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.